Maximum quantity allowed is 999
请选择数量
CAS RN: 117570-53-3 | 產品號碼: D5235
Vadimezan
×
![]()
×
| 包裝 | 價格 | 同一天 | 2-3个工作日 |
|---|---|---|---|
| 50MG |
NT$5,160
|
10 | 聯繫我們 |
| 250MG |
NT$16,520
|
4 | 17 |
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | D5235 |
| 純度/分析方法 | >98.0%(HPLC) |
| 分子式 / 分子量 | C__1__7H__1__4O__4 = 282.30 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Refrigerated (0-10°C) |
| 應避免的情況 | Heat Sensitive |
| 包裝和容器 | 250MG-Glass Bottle with Plastic Insert （閲覽圖片）, 50MG-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 117570-53-3 |
| Reaxys-RN | 4262852 |
| PubChem Substance ID | 468591309 |
| MDL編號 | MFCD00870555 |
產品規格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
性質
| 熔點 | 264 °C |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H302 : Harmful if swallowed. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相關法規
| RTECS # | ZD5536200 |
運輸資料
| HS編碼* | 2932.99-000 |
Application
DMXAA: A Compound Used as a Tumor Vascular Disputing Agent and an Immune Adjuvant
DMXAA (other names: vadimezan, ASA404) is a tumor vascular disputing agent (VDA) that can cause a specific and irreversible destruction of established tumor vessels. Reportedly, DMXAA induces apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core. DMXAA showed anti-tumor effects against solid tumors in mouse models but subsequently failed in human clinical trials in 2010.
DMXAA is also a potent type-I interferon (IFN) inducer, and can be used as an adjuvant that targets a specific innate immune signaling pathway. (The product is for research purpose only.)
DMXAA is also a potent type-I interferon (IFN) inducer, and can be used as an adjuvant that targets a specific innate immune signaling pathway. (The product is for research purpose only.)
References
- An overview on Vadimezan (DMXAA): The vascular disrupting agent (a review)
- The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant
- Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。